View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Sientra Announces Completion and Winning Bidders of its Section 363 Sa...

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra’s breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra’s BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (“Sientra” or the “Company”) announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC (“Tiger”) has been declared t...

 PRESS RELEASE

Sientra to Pursue Strategic Sale of its Business Through Voluntary Cha...

Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on F...

 PRESS RELEASE

Sientra Reports Third Quarter Financial and Operational Results

Sientra Reports Third Quarter Financial and Operational Results IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, a...

 PRESS RELEASE

Sientra to Present at the Stifel 2023 Healthcare Conference

Sientra to Present at the Stifel 2023 Healthcare Conference IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare Conference. As part of the conference, the company’s management team will participate in a live fireside chat on Wednesday, November 15, 2023 at 8:00am EST / 5:00am PST. An on-demand webcast of the presentation will be accessible under “News & Ev...

 PRESS RELEASE

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Res...

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million ...

 PRESS RELEASE

Sientra Reports Record Second Quarter Financial and Operational Result...

Sientra Reports Record Second Quarter Financial and Operational Results Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a s...

 PRESS RELEASE

Sientra to Report Second Quarter 2023 Financial Results on August 10, ...

Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023 IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN)(“Sientra” or the “Company”), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.   The dial-in numbers are (844) 735-3763 for do...

 PRESS RELEASE

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees. The new employees were granted restricted stock units representing a total of 85,750 shares of common stock. The restricted stock units will vest in time-based installments beginning on the grant date. In e...

 PRESS RELEASE

Sientra Announces Appointment of Alexander W. Casdin to Board of Direc...

Sientra Announces Appointment of Alexander W. Casdin to Board of Directors IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023. “On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to...

 PRESS RELEASE

Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue ...

Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander Significant Milestone as the First, and Only, MRI-Compatible Tissue Expander Available on the US Market Continues Sientra’s Leadership and Innovation in Breast Reconstruction IRVINE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510k-clearance for the Company’s novel, patented1 AlloX2 Pro Tiss...

 PRESS RELEASE

Sientra Announces FDA-Clearance of Novel Portfinder™ Technology

Sientra Announces FDA-Clearance of Novel Portfinder™ Technology Continued Innovation Showcases Sientra’s Leadership in Reconstruction Surgeries IRVINE, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510(k) clearance for the Company’s novel Portfinder™ technology. Portfinder™ is an electronic handheld device that allows for the subcutaneous location of ports in Sientra’s De...

 PRESS RELEASE

Sientra Reports Record First Quarter 2023 Operational Results

Sientra Reports Record First Quarter 2023 Operational Results IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eleventh consecutive quarter of year-over-year growth, fueled by market outperformance in reconstruction Continued improvement in non-GAAP OPEX, adjusted EBITDA, and free cash flow performance demonstrating clear pathway to profitability Doubled total addressable market in the United States with commercial launch of Viality™ and SimpliDerm® ADM partnership Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by adva...

 PRESS RELEASE

Sientra to Report First Quarter 2023 Financial Results on May 11, 2023

Sientra to Report First Quarter 2023 Financial Results on May 11, 2023 IRVINE, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time. The dial-in numbers are (877) 270-2148 for domestic callers and (412) 902-...

 PRESS RELEASE

Sientra Reports Record Fourth Quarter and Full Year Revenues and Expan...

Sientra Reports Record Fourth Quarter and Full Year Revenues and Expands Total Addressable Market With New Product Launches Continued 2+ year trend of consecutive record quarterly growth; fastest growing brand in the US breast market Disciplined cash management and enhanced operating leverage for 40% improvement in free cash flow results Significantly increased total addressable market with the launch of Viality™, a novel, FDA-cleared fat transfer technology, and addition of SimpliDerm®, a leading human Acellular Dermal Matrix (ADM) IRVINE, Calif., March 30, 2023 (GLOBE NEWSWIRE) --  (...

 PRESS RELEASE

Sientra to Report Fourth Quarter and Full Year 2022 Financial Results ...

Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 IRVINE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Thursday, March 30, 2023. Sientra will host a conference call to discuss financial results the same day at 4:00 p.m. Eastern Time. The dial-in numbers are (877) 270-2148...

 PRESS RELEASE

Sientra Announces Preliminary Results from Clinical Study and The Firs...

Sientra Announces Preliminary Results from Clinical Study and The First Shipment of Viality™ Fat Transfer System Data Supports Enhanced Viability of Fat in Breast Augmentation and Reconstruction Using the Viality System IRVINE, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it has begun commercial shipping of its Viality™ with AuraClens™ fat transfer system. The Company also announced the release of preliminary results from its on-going, multi-ce...

 PRESS RELEASE

Sientra Announces 1-for-10 Reverse Stock Split

Sientra Announces 1-for-10 Reverse Stock Split IRVINE, Calif., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split was effective at 4:00 p.m. Eastern Time on January 19, 2023. The Company’s common stock is expected to begin trading on The Nasdaq Global Market on a split-adjusted basis on Janu...

 PRESS RELEASE

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SANTA BARBARA, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that on December 27, 2022, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 13 new employees. The new employees were granted restricted stock units representing a total of 902,096 shares of common stock. The restricted stock units will vest in time-based installments beginning on the gran...

 PRESS RELEASE

Sientra Expands Global Footprint With Regulatory Approval to Market Br...

Sientra Expands Global Footprint With Regulatory Approval to Market Breast Implants in the United Arab Emirates IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it has received approval from the United Arab Emirates Ministry of Health and Prevention to market the company’s line of smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in the United Arab Emirates. This new approval marks Sient...

 PRESS RELEASE

Sientra Reports Record Third Quarter 2022 Financial Results

Sientra Reports Record Third Quarter 2022 Financial Results SANTA BARBARA, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced its financial results for the third quarter that ended September 30, 2022. Q3 2022 Financial and Business Highlights Net sales of $22.6 million, representing growth of 15% over the third quarter of 2021Year-to-date net sales of $65.5 million, representing growth of nearly 13% compared to the same period...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch